Literature DB >> 28691138

The Importance of Parameters: MPV, MPV/Thrombocyte Ratio and Neutrophil/Lymphocyte Ratio in Sorafenib Treatment Response of Patients with Hepatocellular Cancer.

Ali Oğul1, Berksoy Şahin2, Ferit Kuşçu3, Onur Taktakoğlu4, Abdullah Evren Yetişir2, Mahmut Büyükşimşek2, Cem Mirili2, Serkan Gökçay2, M Gökhan Gök5, Pınar Kum6.   

Abstract

Entities:  

Year:  2017        PMID： 28691138     DOI： 10.1007/s12029-017-9970-5

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  3 in total

1.  Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer.

Authors:  Muhyettin Omar; Ozgur Tanriverdi; Suna Cokmert; Esin Oktay; Ozlem Yersal; Kezban Nur Pilancı; Serkan Menekse; Muharrem Kocar; Cenk Ahmet Sen; Cetin Ordu; Gamze Goksel; Nezih Meydan; Sabri Barutca
Journal:  Clin Respir J       Date:  2017-01-06       Impact factor: 2.570

2.  Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

Authors:  Nicola Personeni; Silvia Bozzarelli; Tiziana Pressiani; Lorenza Rimassa; Maria Chiara Tronconi; Francesco Sclafani; Carlo Carnaghi; Vittorio Pedicini; Laura Giordano; Armando Santoro
Journal:  J Hepatol       Date:  2012-03-10       Impact factor: 25.083

3.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.